Filing Details
- Accession Number:
- 0001209191-19-029049
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2019-05-10 17:34:14
- Reporting Period:
- 2019-04-01
- Accepted Time:
- 2019-05-10 17:34:14
- Original Submission Date:
- 2019-04-03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1724605 | Carole Ho | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-04-01 | 5,775 | $5.28 | 5,775 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-01 | 5,775 | $23.91 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2019-04-02 | 6,242 | $5.28 | 6,242 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-02 | 2,800 | $24.51 | 3,442 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-02 | 3,442 | $25.15 | 0 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-02 | 9,445 | $25.29 | 132,670 | No | 4 | S | Indirect | See footnote |
Common Stock | Acquisiton | 2019-04-03 | 5,862 | $5.28 | 5,862 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-03 | 5,262 | $26.27 | 600 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-03 | 600 | $26.81 | 0 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-03 | 8,688 | $26.29 | 123,982 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2019-04-03 | 900 | $26.79 | 123,082 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Indirect | See footnote |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-01 | 5,775 | $0.00 | 5,775 | $5.28 |
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-02 | 6,242 | $0.00 | 6,242 | $5.28 |
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-03 | 5,862 | $0.00 | 5,862 | $5.28 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
105,855 | 2027-03-07 | No | 4 | M | Direct | |
99,613 | 2027-03-07 | No | 4 | M | Direct | |
93,751 | 2027-03-07 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 46,875 | Direct | |
Common Stock | 25,000 | Indirect | See footnote |
Footnotes
- The shares are held of record by Carole Ho and Rajat Rohatgi.
- The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.35 to $24.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- This Form 4 amendment is being filed to correct an omission on the Form 4 filed on behalf of the Reporting Person on April 3, 2019. The original Form 4 filed did not reflect an additional 107 shares exercised from outstanding stock options and sold on April 2, 2019 pursuant to the Issuer's 10b5-1 plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.81 to $24.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.82 to $25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.00 to $25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.73 to $26.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $26.75 to $26.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.73 to $26.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.